Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

MTVABullishCorporate Developmentsnews

High materiality7/10

MetaVia appoints veteran CMO ahead of Q4 2026 DA-1726 data

Oct 13, 2026, 8:47 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Leadership addition plus a forthcoming Phase 1 readout can improve execution perception and raise odds of eventual data-driven valuation upside.

AI summary

What happened, with direct paths to the underlying reporting

MetaVia appointed Dr. Sarah Browne as Chief Medical Officer, effective Oct 12, 2026, adding 20+ years in liver and metabolic diseases and experience with pemvidutide. The company also notes a Q4 2026 topline readout from DA-1726 Part 3 and ongoing MASH work with vanoglipel, underscoring a near-term data-driven catalyst and pipeline progression.

MetaVia names Dr. Sarah Browne as CMO, effective Oct 12, 2026. Brings 20+ years in liver/metabolic drug development.
Phase 1 Part 3 DA-1726 topline data expected Q4 2026. Doses 48 mg and 64 mg evaluated.
Vanoglipel (DA-1241) for MASH with hepatic benefits. Phase 2a hepatic action observed.
Pemvidutide expertise underscores dual GLP-1/GCGR development focus. Strategic for DA-1726/DA-1241.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.